Compile Data Set for Download or QSAR
Report error Found 28 Enz. Inhib. hit(s) with all data for entry = 646
TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(US10077265, Example 5 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 0.800nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285515(US10077265, Example 2 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 2.5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285515(US10077265, Example 2 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 2.70nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(US10077265, Example 5 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 2.70nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285522(US10077265, Example 9 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285527(US10077265, Example 14 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 3.80nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285521(US10077265, Example 8 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 3.80nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285525(US10077265, Example 12 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285514(US10077265, Example 1 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285526(US10077265, Example 13 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 5.20nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(US10077265, Example 5 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 5.40nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285520(US10077265, Example 7 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 6.40nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285524(US10077265, Example 11 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 6.60nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285523(US10077265, Example 10 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 9.5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285516(US10077265, Example 3 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(US10077265, Example 5 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285514(US10077265, Example 1 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 17nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285527(US10077265, Example 14 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 18nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285519(US10077265, Example 6 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 18nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285522(US10077265, Example 9 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 28nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285521(US10077265, Example 8 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 29nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285525(US10077265, Example 12 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 33nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285526(US10077265, Example 13 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 38nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285524(US10077265, Example 11 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 44nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285523(US10077265, Example 10 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 47nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285520(US10077265, Example 7 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 51nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285519(US10077265, Example 6 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 93nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285516(US10077265, Example 3 | 5-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 120nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent